Trials / Completed
CompletedNCT00086203
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Point Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.
Detailed description
Completion date provided represents the completion date of the grant per OOPD records
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talabostat mesylate (PT-100) tablets | |
| DRUG | Rituximab |
Timeline
- Completion
- 2007-09-01
- First posted
- 2004-06-29
- Last updated
- 2015-03-25
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00086203. Inclusion in this directory is not an endorsement.